utologous matrix-induced chondrogenesis (AMIC) is a 1-step cartilage restoration technique that combines microfracture with the use of an exogenous scaffold.
The functional principle of microfracturing is based on the release of multipotent mesenchymal progenitor cells, cytokines and growth factors from the subchondral bone. 

The global Autologous Matrix-induced Chondrogenesis market was valued at 100 million US$ in 2018 and will reach 180 million US$ by the end of 2025, growing at a CAGR of 7.6% during 2019-2025.
This report focuses on Autologous Matrix-induced Chondrogenesis volume and value at global level, regional level and company level. From a global perspective, this report represents overall Autologous Matrix-induced Chondrogenesis market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Autologous Matrix-induced Chondrogenesis in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Autologous Matrix-induced Chondrogenesis manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Poly Lactic-Co-Glycolic Acid (PGLA)

Segment by Application
Knees Joint
Other